INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2019

Oral saffron supplementation modestly improved visual acuity and electroretinogram parameters in adults with mild to moderate age-related macular degeneration.

A randomized, double-blinded, placebo-controlled crossover trial evaluated the effects of 20 mg/day oral saffron versus placebo for 3 months each in 100 adults with mild/moderate age-related macular degeneration. Mean BCVA improved by 0.69 letters (p = 0.001) and mean-pooled mfERG latency decreased by 0.17 ms (p = 0.04) on saffron compared to placebo. In participants also taking AREDS supplements, mean BCVA improved by 0.73 letters (p = 0.006) and mfERG response density improved by 2.8% (p = 0.038). Adverse events did not differ significantly between groups (p > 0.10).

Study type
Randomised, double-blinded, placebo-controlled crossover trial
Who was studied
100 adults (> 50 years) with mild/moderate age-related macular degeneration
What was measured
Best-corrected visual acuity (BCVA) and multifocal electroretinogram (mfERG) response density and latency

THE PAPER

Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial.

Broadhead GK, Grigg JR, McCluskey P, Hong T, Schlub TE, Chang AA. Graefes Arch Clin Exp Ophthalmol, 2019.

PubMed 30343354 ↗DOI 10.1007/s00417-018-4163-x ↗

Healthy aging & longevityOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.